



516/2021/AR

| Company | LT fundamental recommendation | 12M EFV (PLN) | ST market-relative bias | Analyst |
|------------------|-------------------------------|---------------|-------------------------|---|
| BioMaxima | Not rated | 37.3 | Not rated | Sylvia Jaśkiewicz, CFA +48 571 232 030 Mikołaj Stępień +48 504 949 345 |

Event: Insider trading

After Friday's close, the Company informed that Henryk Lewczuk, the Management Vice-President, sold 2,000 shares, each per PLN 24. The transaction was executed on October 5 and its value reached PLN 48,000.

Expected impact: *The transaction value was low.*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.